Abatacept for the Treatment of Myositis-associated Interstitial Lung Disease
Status:
Recruiting
Trial end date:
2022-05-30
Target enrollment:
Participant gender:
Summary
A randomized, controlled pilot trial to evaluate the efficacy and safety of subcutaneous
Abatacept in treating interstitial lung disease associated with the anti-synthetase syndrome.